BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, Escaff S, Vizoso FJ. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother. 2011;60:217-226. [PMID: 20978888 DOI: 10.1007/s00262-010-0931-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Alam MJ, Bardakci F, Anjum S, Mir SR, Ahmad I, Saeed M. Molecular docking analysis of p53 with Toll-like receptors. Bioinformation 2021;17:784-9. [PMID: 35539888 DOI: 10.6026/97320630017784] [Reference Citation Analysis]
2 Ehsan N, Murad S, Ashiq T, Mansoor MU, Gul S, Khalid S, Younas M. Significant correlation of TLR4 expression with the clinicopathological features of invasive ductal carcinoma of the breast. Tumour Biol 2013;34:1053-9. [PMID: 23338716 DOI: 10.1007/s13277-013-0645-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
3 Patra MC, Shah M, Choi S. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Semin Cancer Biol 2020;64:61-82. [PMID: 31054927 DOI: 10.1016/j.semcancer.2019.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
4 Ji X, Meng W, Liu Z, Mu X. Emerging Roles of lncRNAs Regulating RNA-Mediated Type-I Interferon Signaling Pathway. Front Immunol 2022;13:811122. [DOI: 10.3389/fimmu.2022.811122] [Reference Citation Analysis]
5 Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, Ran S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 2014;74:5421-34. [PMID: 25274031 DOI: 10.1158/0008-5472.CAN-14-0067] [Cited by in Crossref: 127] [Cited by in F6Publishing: 76] [Article Influence: 18.1] [Reference Citation Analysis]
6 Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B, Fresno-Forcelledo MF, Rodrigo L. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769-778. [PMID: 23742263 DOI: 10.1111/hepr.12180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
7 Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 2012;61:453-68. [PMID: 22331081 DOI: 10.1007/s00262-012-1216-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
8 Ou T, Zhou Z, Turner DP, Zhu B, Lilly M, Jiang W. Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients. Front Oncol 2019;9:1532. [PMID: 32010622 DOI: 10.3389/fonc.2019.01532] [Reference Citation Analysis]
9 Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther 2017;2:17055. [PMID: 29263932 DOI: 10.1038/sigtrans.2017.55] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
10 Beilmann-Lehtonen I, Böckelman C, Mustonen H, Koskensalo S, Hagström J, Haglund C. The prognostic role of tissue TLR2 and TLR4 in colorectal cancer. Virchows Arch 2020;477:705-15. [PMID: 32424768 DOI: 10.1007/s00428-020-02833-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Moreira D, Zhang Q, Hossain DM, Nechaev S, Li H, Kowolik CM, D'Apuzzo M, Forman S, Jones J, Pal SK, Kortylewski M. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget 2015;6:17302-13. [PMID: 26046794 DOI: 10.18632/oncotarget.4029] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
12 Ma X, Wang H, Zhang P, Xu L, Tian Z. Association between small intestinal bacterial overgrowth and toll-like receptor 4 in patients with pancreatic carcinoma and cholangiocarcinoma. Turk J Gastroenterol 2019;30:177-83. [PMID: 30457560 DOI: 10.5152/tjg.2018.17512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Traka MH, Melchini A, Mithen RF. Sulforaphane and prostate cancer interception. Drug Discov Today 2014;19:1488-92. [PMID: 25051139 DOI: 10.1016/j.drudis.2014.07.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
14 Yeh DW, Huang LR, Chen YW, Huang CF, Chuang TH. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res 2016;2016:4368101. [PMID: 28116318 DOI: 10.1155/2016/4368101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
15 Huhta H, Helminen O, Kauppila JH, Takala H, Metsikkö K, Lehenkari P, Saarnio J, Karttunen T. Toll-like receptor 9 expression in the natural history of Barrett mucosa. Virchows Arch 2015;467:9-18. [PMID: 25838081 DOI: 10.1007/s00428-015-1770-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
16 Wang Q, Zhang X, Xiao T, Pan C, Liu X, Zhao Y. Prognostic role of Toll-like receptors in cancer: a meta-analysis. Ther Clin Risk Manag 2018;14:1323-30. [PMID: 30104878 DOI: 10.2147/TCRM.S171341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
17 Ran S. The Role of TLR4 in Chemotherapy-Driven Metastasis. Cancer Res. 2015;75:2405-2410. [PMID: 25998620 DOI: 10.1158/0008-5472.can-14-3525] [Cited by in Crossref: 67] [Cited by in F6Publishing: 28] [Article Influence: 9.6] [Reference Citation Analysis]
18 Matijevic T, Pavelic J. The dual role of TLR3 in metastatic cell line. Clin Exp Metastasis 2011;28:701-12. [PMID: 21735101 DOI: 10.1007/s10585-011-9402-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kim JK, Jung Y, Wang J, Joseph J, Mishra A, Hill EE, Krebsbach PH, Pienta KJ, Shiozawa Y, Taichman RS. TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia 2013;15:1064-74. [PMID: 24027431 DOI: 10.1593/neo.13402] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
20 Han JH, Park JH, Kim BY, Chang SN, Kim TH, Park JH, Kim DJ. Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice. J Vet Sci 2015;16:281-7. [PMID: 25797291 DOI: 10.4142/jvs.2015.16.3.281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Väisänen MR, Jukkola-Vuorinen A, Vuopala KS, Selander KS, Vaarala MH. Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer. Oncol Lett 2013;5:1659-63. [PMID: 23761830 DOI: 10.3892/ol.2013.1204] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
22 Leonardi R, Perrotta RE, Crimi S, Matthews JB, Barbato E, dos Santos JN, Rusu M, Bufo P, Bucci P, Pannone G. Differential expression of TLR3 and TLR4 in keratocystic odontogenic tumor (KCOT): A comparative immunohistochemical study in primary, recurrent, and nevoid basal cell carcinoma syndrome (NBCCS)--associated lesions. J Craniomaxillofac Surg 2015;43:733-7. [PMID: 25976039 DOI: 10.1016/j.jcms.2015.03.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Kalantari E, Abolhasani M, Roudi R, Farajollahi MM, Farhad S, Madjd Z, Askarian-Amiri S, Mohsenzadegan M. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Int J Exp Pathol 2019;100:123-32. [PMID: 31090157 DOI: 10.1111/iep.12314] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
24 A J, Zhang B, Zhang Z, Hu H, Dong JT. Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer. Cancers (Basel) 2021;13:917. [PMID: 33671634 DOI: 10.3390/cancers13040917] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Pillai S, Nguyen J, Johnson J, Haura E, Coppola D, Chellappan S. Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis. Nat Commun 2015;6:10072. [PMID: 26656453 DOI: 10.1038/ncomms10072] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
26 Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297-1316. [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 11.7] [Reference Citation Analysis]
27 Luo Q, Hu S, Yan M, Sun Z, Chen W, Chen F. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo. Int J Biochem Cell Biol 2012;44:1266-75. [PMID: 22568929 DOI: 10.1016/j.biocel.2012.04.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
28 Miyar A, Habibi I, Ebrahimi A, Mansourpour D, Mokarizadeh A, Rajabi A, Farshgar R, Eshaghzadeh M, Zamani-ahmadmahmudi M, Nodushan SMHT. Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis. Journal of the Neurological Sciences 2016;368:314-7. [DOI: 10.1016/j.jns.2016.07.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Sun M, Geng D, Li S, Chen Z, Zhao W. LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem 2018;399:387-95. [PMID: 29261512 DOI: 10.1515/hsz-2017-0255] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
30 Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, Lymperi M, Gazouli M, Zografos GC. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast. 2012;21:534-538. [PMID: 22560646 DOI: 10.1016/j.breast.2012.04.001] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
31 Cen X, Liu S, Cheng K. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Front Pharmacol 2018;9:878. [PMID: 30127747 DOI: 10.3389/fphar.2018.00878] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
32 Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011;2011:609579. [PMID: 22110526 DOI: 10.1155/2011/609579] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 8.2] [Reference Citation Analysis]
33 Alvarado-Morales I, Olivares-Illana V, Arenas-Huertero C, Reynaga-Hernández E, Layseca-Espinosa E, Tokar EJ, Escudero-Lourdes C. Human prostate epithelial cells and prostate-derived stem cells malignantly transformed in vitro with sodium arsenite show impaired Toll like receptor -3 (TLR3)-associated anti-tumor pathway. Toxicol Lett 2021;350:185-93. [PMID: 34303791 DOI: 10.1016/j.toxlet.2021.07.013] [Reference Citation Analysis]
34 He Z, Huang X, Ni Y, Shi P, Wang Z, Han W, Hu Q. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014;118:92-100. [DOI: 10.1016/j.oooo.2014.03.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
35 Eiró N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg 2012; 4(3): 62-72 [PMID: 22530080 DOI: 10.4240/wjgs.v4.i3.62] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
36 Jinushi M. Yin and yang of tumor inflammation: how innate immune suppressors shape the tumor microenvironments. Int J Cancer 2014;135:1277-85. [PMID: 24272248 DOI: 10.1002/ijc.28626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
37 Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S, Haupt Y. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. Int J Mol Sci 2020;21:E3452. [PMID: 32414156 DOI: 10.3390/ijms21103452] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
38 Bayraktar R, Bertilaccio MTS, Calin GA. The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. Front Immunol 2019;10:1053. [PMID: 31139186 DOI: 10.3389/fimmu.2019.01053] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
39 Sfanos KS, Hempel HA, De Marzo AM. The role of inflammation in prostate cancer. Adv Exp Med Biol. 2014;816:153-181. [PMID: 24818723 DOI: 10.1007/978-3-0348-0837-8_7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 8.1] [Reference Citation Analysis]
40 Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J, Ren T, Gutkind JS. MicroRNA-7–regulated TLR9 signaling–enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. MBoC 2013;24:42-55. [DOI: 10.1091/mbc.e12-07-0519] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
41 Misawa A, Takayama KI, Fujimura T, Homma Y, Suzuki Y, Inoue S. Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells. Cancer Sci 2017;108:373-9. [PMID: 28032932 DOI: 10.1111/cas.13151] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
42 Sellami H, Said-Sadier N, Znazen A, Gdoura R, Ojcius DM, Hammami A. Chlamydia trachomatis infection increases the expression of inflammatory tumorigenic cytokines and chemokines as well as components of the Toll-like receptor and NF-κB pathways in human prostate epithelial cells. Mol Cell Probes 2014;28:147-54. [PMID: 24613856 DOI: 10.1016/j.mcp.2014.01.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
43 Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012;61:667-676. [PMID: 22038398 DOI: 10.1007/s00262-011-1132-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
44 Bishop JL, Davies A, Ketola K, Zoubeidi A. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer 2015;22:R165-82. [PMID: 25934687 DOI: 10.1530/ERC-15-0137] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
45 Giurini EF, Madonna MB, Zloza A, Gupta KH. Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression. Cancers (Basel) 2022;14:2923. [PMID: 35740589 DOI: 10.3390/cancers14122923] [Reference Citation Analysis]
46 Pandey NO, Chauhan AV, Raithatha NS, Patel PK, Khandelwal R, Desai AN, Choxi Y, Kapadia RS, Jain ND. Association of TLR4 and TLR9 polymorphisms and haplotypes with cervical cancer susceptibility. Sci Rep. 2019;9:9729. [PMID: 31278284 DOI: 10.1038/s41598-019-46077-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
47 Han S, Xu W, Wang Z, Qi X, Wang Y, Ni Y, Shen H, Hu Q, Han W. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment. Oncotarget 2016;7:37773-89. [PMID: 27191981 DOI: 10.18632/oncotarget.9329] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
48 Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol 2016;52:9-18. [PMID: 26980049 DOI: 10.1016/j.humpath.2016.01.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
49 Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12:1676-1687. [PMID: 23720768 DOI: 10.1158/1535-7163.mct-12-1019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 48] [Article Influence: 8.8] [Reference Citation Analysis]
50 Tarang S, Kumar S, Batra SK. Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett 2012;321:110-9. [PMID: 22306702 DOI: 10.1016/j.canlet.2012.01.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
51 Zhang Y, Wang Y, Yuan J, Qin W, Liu F, Wang F, Zhang G, Yang X. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol Toxicol 2012;28:269-77. [DOI: 10.1007/s10565-012-9221-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
52 Eiró N, González L, González LO, Andicoechea A, Fernández-Díaz M, Altadill A, Vizoso FJ. Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol. 2012;32:848-854. [PMID: 22371291 DOI: 10.1007/s10875-012-9666-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
53 Yu L, Wang L, Chen S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cell Mol Life Sci 2012;69:935-49. [DOI: 10.1007/s00018-011-0864-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
54 Boufraqech M, Fassassi C, Kebebew E. TLR-10 polymorphism and papillary thyroid cancer: one more SNP to consider? Endocrine 2013;43:10-1. [PMID: 23138464 DOI: 10.1007/s12020-012-9827-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther 2013;6:1573-87. [PMID: 24235843 DOI: 10.2147/OTT.S50838] [Cited by in Crossref: 19] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
56 Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T. A Compressive Review about Taxol®: History and Future Challenges. Molecules 2020;25:E5986. [PMID: 33348838 DOI: 10.3390/molecules25245986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Taghavi Pourianazar N, Gunduz U. CpG oligodeoxynucleotide-loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells. Biomed Pharmacother 2016;78:81-91. [PMID: 26898428 DOI: 10.1016/j.biopha.2016.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
58 Luo Y, Jiang QW, Wu JY, Qiu JG, Zhang WJ, Mei XL, Shi Z, Di JM. Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer. Oncotarget 2015;6:22564-74. [PMID: 26087186 DOI: 10.18632/oncotarget.4197] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
59 Muresan XM, Bouchal J, Culig Z, Souček K. Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance. Cancers (Basel) 2020;12:E3227. [PMID: 33147700 DOI: 10.3390/cancers12113227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
60 Zheng X, Li S, Yang H. Roles of Toll-Like Receptor 3 in Human Tumors. Front Immunol 2021;12:667454. [PMID: 33986756 DOI: 10.3389/fimmu.2021.667454] [Reference Citation Analysis]
61 Wang K, Wang J, Wei F, Zhao N, Yang F, Ren X. Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy. Front Immunol 2017;8:456. [PMID: 28484456 DOI: 10.3389/fimmu.2017.00456] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
62 Gaudreau PO, Stagg J, Soulières D, Saad F. The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomark Cancer 2016;8:15-33. [PMID: 27168728 DOI: 10.4137/BIC.S31802] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
63 Ohadian Moghadam S, Nowroozi MR. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol 2019;90. [DOI: 10.1111/sji.12818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
64 Pandey N, Chauhan A, Jain N. TLR4 Polymorphisms and Expression in Solid Cancers. Mol Diagn Ther 2018;22:683-702. [PMID: 30311146 DOI: 10.1007/s40291-018-0361-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
65 Seif F, Sharifi L, Khoshmirsafa M, Mojibi Y, Mohsenzadegan M. A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer. Curr Drug Targets 2019;20:789-98. [PMID: 30674255 DOI: 10.2174/1389450120666190123141553] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
66 Matijevic Glavan T, Cipak Gasparovic A, Vérillaud B, Busson P, Pavelic J. Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF. Mol Carcinog 2017;56:1214-26. [PMID: 27805282 DOI: 10.1002/mc.22584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
67 Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
68 Ou T, Lilly M, Jiang W. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer. Front Immunol 2018;9:1188. [PMID: 29928275 DOI: 10.3389/fimmu.2018.01188] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
69 Sootichote R, Thuwajit P, Singsuksawat E, Warnnissorn M, Yenchitsomanus PT, Ithimakin S, Chantharasamee J, Thuwajit C. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer 2018;18:231. [PMID: 29486738 DOI: 10.1186/s12885-018-4155-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
70 Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth Metastasis 2015;8:25-34. [PMID: 26279628 DOI: 10.4137/CGM.S24314] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
71 Eiró N, Ovies C, Fernandez-Garcia B, Álvarez-Cuesta CC, González L, González LO, Vizoso FJ. Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. Arch Dermatol Res 2013;305:59-67. [PMID: 23179584 DOI: 10.1007/s00403-012-1300-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
72 Leppänen J, Helminen O, Huhta H, Kauppila JH, Isohookana J, Haapasaari KM, Lehenkari P, Saarnio J, Karttunen TJ. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Virchows Arch 2017;470:401-10. [PMID: 28191612 DOI: 10.1007/s00428-017-2087-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
73 Lee C, Dang A, Hernandez E, Pong R, Chen B, Sonavane R, Raj G, Kapur P, Lin H, Wu S, Ko C, Lo U, Lee H, Hsieh J, Lee M. Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase. Oncogene 2019;38:5580-98. [DOI: 10.1038/s41388-019-0833-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
74 Huang S, Chang T, Chao CC, Sun N. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells. Biochemical Pharmacology 2020;177:113965. [DOI: 10.1016/j.bcp.2020.113965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Al-Kahiry WMA, Dammag EAM, Abdelsalam HST, Fadlallah HK, Owais MS. Toll-like receptor 9 negatively related to clinical outcome of AML patients. J Egypt Natl Canc Inst 2020;32:15. [PMID: 32372371 DOI: 10.1186/s43046-020-00027-3] [Reference Citation Analysis]
76 Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol 2014;5:352. [PMID: 25101092 DOI: 10.3389/fimmu.2014.00352] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
77 Feng Y, Chen Y, Meng Y, Cao Q, Liu Q, Ling C, Wang C. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy. Oncoimmunology 2018;7:e1426434. [PMID: 29721392 DOI: 10.1080/2162402X.2018.1426434] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
78 Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology 2017;222:89-100. [PMID: 27349597 DOI: 10.1016/j.imbio.2016.06.009] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 13.8] [Reference Citation Analysis]
79 Gambara G, De Cesaris P, De Nunzio C, Ziparo E, Tubaro A, Filippini A, Riccioli A. Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med. 2013;17:713-722. [PMID: 23551576 DOI: 10.1111/jcmm.12055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
80 Gowing SD, Cool-Lartigue JJ, Spicer JD, Seely AJE, Ferri LE. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clin Exp Metastasis 2020;37:225-39. [PMID: 31975313 DOI: 10.1007/s10585-020-10018-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
81 Kourko O, Smyth R, Cino D, Seaver K, Petes C, Eo SY, Basta S, Gee K. Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment. J Interferon Cytokine Res 2019;39:483-94. [PMID: 31009295 DOI: 10.1089/jir.2018.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
82 Gambara G, Desideri M, Stoppacciaro A, Padula F, De Cesaris P, Starace D, Tubaro A, Del Bufalo D, Filippini A, Ziparo E, Riccioli A. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med 2015;19:327-39. [PMID: 25444175 DOI: 10.1111/jcmm.12379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]